DNM1L and Alzheimer disease: In AD, in addition to elevated Drp-1 levels (p ≤ 0.0001) and reduced Opa-1 levels (p ≤ 0.0001), an increase in Mfn-2 levels was also detected (p = 0.0001) (Figure 3G–I).